Apple Podcasts 
YouTube 
Spotify 
iHeartRadio 
Podchaser 
RSS Feed 
Amazon Music 
Podcast Addict 
PocketCasts 
Deezer 
PlayerFM 
Castro 
Castbox 
Goodpods Biotech IR Across Development Stages
Michael Loftus of POC Capital on how biotech investor relations must adapt at every stage — from early clinical work, to mid-stage asset visibility, to late-stage commercialization.
In this episode of The Investor Relations Podcast, Michael Loftus, Biotech Growth Architect and Family Office Strategist, breaks down how investor relations strategies must adapt across the different stages of a biotech company’s growth. Drawing on his experience in capital markets and life sciences, Michael explains how IR leaders and executives can communicate more effectively with investors depending on whether their company is early-stage, mid-stage, or preparing for commercialization.
The conversation highlights why investors often place their confidence in the team during early-stage development, how mid-stage companies should emphasize asset value and visibility through investor conferences, and what late-stage biotechs must do to showcase the real-world impact of their products. For biotech executives, IR professionals, and capital markets stakeholders, this episode offers a practical roadmap for aligning investor communications with company maturity.
#InvestorRelations #Biotech #LifeSciences #CapitalMarkets #BiotechInvesting #ShareholderEngagement
Connect with the Guest
- Company: https://www.poccap.com
- LinkedIn: https://www.linkedin.com/in/mikeloftusclinicaltrials/
- Podcast profile: View all of their episodes here
Connect with the Host
- Joshua Wilson LinkedIn: https://www.linkedin.com/in/joshuabrucewilson/
- The Investor Relations Podcast YouTube channel: https://www.youtube.com/@TheInvestorRelationsPodcast
Contact Link
https://www.theinvestorrelationspodcast.com/contact/
Topics: biotech IR across development stages, life sciences investor relations, early-stage biotech communications, biotech investor conferences, late-stage biotech commercialization, IR for clinical-stage companies, family office biotech investing
Disclaimer: Joshua Wilson is a licensed Florida real estate broker and holds FINRA Series 79 and Series 63 licensure. The content of this podcast is for informational and educational purposes only and should not be considered legal, financial, or compliance advice. All views and opinions expressed by the host and guests are their own and do not necessarily reflect the policies or positions of any regulatory agency, organization, or employer. Listeners should consult their own legal counsel, compliance teams, or financial advisors to ensure adherence to applicable regulations, including SEC, FINRA, and other industry-specific requirements. This podcast does not constitute a solicitation or recommendation for any financial products or services.
Let’s Connect on LinkedIn:
https://www.linkedin.com/in/joshuabrucewilson/
To Contact Us, Please Visit:
Joshua:
With biotech, right? Sometimes there are different phases in the stage of the company. What are some IR strategies for maybe the different phases or stages of a biotech company?
Michael Loftus:
Sure. When you're first starting out—let's say you're pre-clinical moving into clinical—I think you really need to highlight the team working on the project and the pipeline. People are still investing in the jockeys at that point. The assets are secondary, I think, at first. If you have the best team in the world, they can get a mediocre asset to market. Versus a team of maybe really excited, smart people who don’t really have any experience—they might not know the pitfalls and pratfalls of how to get through certain hurdles along the way. So I think you highlight the team and your experience.
If you're a little further advanced, I think you really need to focus on the asset value—what you're working on—and really get it out to the market through investment banking channels. There are a lot of great investment banking conferences that these companies can attend. Face-to-face connection is really good when you have something to invest in.
And then if you're late stage, obviously it’s about kicking out the product and showcasing what it really has behind it—the different aspects of how it can serve that patient population.